Ferrosan's 2008 revenue jumps 9%

Ferrosan, a Danish consumer and health care company, says its full-year 2008 revenues grew 9% year-on-year to 1.32 billion Danish kroner ($223.0  million), as operating profit rose 10% to 269.0 million kroner.

According to the firm, its consumer brands Multi-tabs, Idoform, the  eye-care product Strix and the joint-care product Zinaxin realized an  increase in revenues of 7% in total. A large part of the growth was  achieved in Russia and Ukraine, where the revenues rose 12% and 9%,  respectively. Ferrosan core brands are now positioned as market  leaders in these countries, the firm noted.

Sales of probiotics under the Idoform and Bifiform brands soared 31%,  while the combined vitamin and probiotics product, Immuno, was an  important contributor to the growth within the adult segment.